From 'Green Light' Sector to Restructuring Hotspot?  

For many years, pharmacy was regarded as a low-risk, 'green light' sector by lenders and investors alike. Performance was attractive and predictable, meaning for well-established operators, finance was easy to come by with EBITDA comfortably servicing their lending requirements. 

However, cracks started to appear in that financial model after 2019. The five-year NHS funding agreement that was introduced that year failed to anticipate the sharp inflationary pressures that followed. Energy, wages, and inventory costs all increased materially, yet pharmacy funding remained flat. This resulted in margin compression across the sector, with EBITDA being increasingly insufficient to absorb both the rising operating costs and higher interest rates.

A recurring theme in many distressed situations has been an over-reliance on NHS income. Operators that failed to diversify into higher-margin private and enhanced services were particularly exposed. Pharmacy First, contraception services, vaccination programmes, travel health, and private weight loss medications such as Mounjaro now represent significant opportunities, but uptake has not been universal. In the most extreme examples, the issues discussed above have been compounded by mismanagement or unsuccessful strategic decisions, leading to terminal breakdowns in businesses and ultimately insolvency.

Political uncertainty further exacerbated matters. The 2024 General Election resulted in the existing five-year funding deal being rolled forward rather than renegotiated. With costs continuing to rise, margins narrowed further, and EBITDA, which once comfortably covered mortgage repayments, became acutely sensitive to even minor shocks.

A new two-year funding deal was eventually agreed and implemented in April 2025, but backdated to 2024, meaning it only ran until April 2026. This means the sector is once again in a limbo period, operating under an expired agreement while awaiting clarity on future funding. Many of the trade representative bodies and operators alike continue to argue publicly that pharmacy is structurally underfunded; however, the Government’s position remains that pharmacies should be treated like any other business. They should not rely solely on NHS funding but instead maximise income from private and commissioned services.

Despite the negative press, however, demand for pharmacy opportunities remains strikingly strong, with sustained interest from both existing operators and new entrants either seeking to expand or enter the market. This suggests that, while the sector is undoubtedly under pressure, it is not uniformly broken. For well-capitalised buyers with operational expertise and a diversified income strategy, distress may represent an opportunity. For turnaround professionals, pharmacy has evolved from a defensive sector to one requiring active intervention.

If you would like a confidential discussion on how our brokerage, valuation, or advisory services can add value to your restructuring/recovery process, please contact Ben Thompson: ben.thompson@christie.com or 07756 875 226